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Abstract
Background: Wilson’s disease (WND) is a rare autosomal recessive disorder. Here we have evaluated 62 WND cases
(58 probands) from the Chinese Han population to expand our knowledge of ATP7B mutations and to more
completely characterize WND in China.
Methods: The coding and promoter regions of the ATP7B gene were analyzed by direct sequencing in 62 Chinese
patients (58 probands) with WND (male, n = 37; female, n = 25; age range, 2 ~ 61 years old).
Results: Neurologic manifestations were associated with older age at diagnosis (p < 0.0001) and longer diagnostic
delay (p < 0.0001). Age at diagnosis was also correlated with urinary copper concentration (r = 0.58, p < 0.001).
Forty different mutations, including 14 novel mutations, were identified in these patients. Common mutations
included p.Arg778Leu (31.9%) and p.Pro992Leu (11.2%). Homozygous p.Arg778Leu and nonsense mutation/
frameshift mutations were more often associated with primary hepatic manifestations (p = 0.0286 and p = 0.0383,
respectively) and higher alanine transaminase levels at diagnosis (p = 0.0361 and p = 0.0047, respectively).
Nonsense mutation/frameshift mutations were also associated with lower serum ceruloplasmin (p = 0.0065).
Conclusions: We identified 14 novel mutations and found that the spectrum of mutations of ATP7B in China is
quite distinct from that of Western countries. The mutation type plays a role in predicting clinical manifestations.
Genetic testing is a valuable tool to detect WND in young children, especially in patients younger than 8 years old.
Four exons (8, 12, 13, and 16) and two mutations (p.Arg778Leu, p.Pro992Leu) should be considered high priority
for cost-effective testing in China.
Background
Wilson’s disease (WND; OMIM#277900) is a rare auto-
somal recessive disorder that is caused by abnormal
copper metabolism; its prevalence is approximately 30
cases per million people [1-4]. The excessive copper
accumulation in various organs, primarily the liver,
brain, kidney, and cornea, results in a spectrum of hepa-
tic and neurologic abnormalities [5-7]. Clinical presenta-
tion is highly heterogeneous [8,9]; patients can present
with hepatic symptoms, neurologic symptoms, or both.
The age of onset ranges from 2 to 70 years [10-12].
Diagnosis of WND is based on clinical symptoms (hepa-
tic symptoms, neurologic symptoms, and cornea Kayser-
Fleischer ring) and biochemical tests (elevated 24-h
urinary copper, low plasma ceruloplasmin, and elevated
liver copper concentrations) [1,2]. However, biochemical
markers can be misleading [1,2], rendering WND diag-
nosis difficult in the absence of typical symptoms. For
that reason, genetic testing has become the method of
choice to establish a precise diagnosis [2,3].
The gene responsible for WND was first identified in
1993 and encodes a copper-transporting P-type ATPase
(ATP7B; OMIM *606882) [13-15]. It is located on chro-
mosome 13 (13q14.3-q21.1) and consists of 21 exons,
which span a DNA region of approximately 100 kb. The
ATP7B gene encodes 1465-amino acid membrane pro-
tein [13,15,16] that consists of six metal-binding
domains, eight transmembrane segments, an ATP-bind-
ing domain typical of copper ATPases with a P-domain,
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motif [17-19]. ATP7B is a transporter in the copper
secretory pathway that delivers copper for incorporation
into apoceruloplasmin and excretion into the bile [6,20].
Impaired ATP7B function results in excessive cellular
copper accumulation, thereby causing WND.
To date, more than 500 mutations have been identi-
fied in patients with WND, (Human Gene Mutation
Database (Cardiff): http://www.hgmd.cf.ac.uk/ac/index.
php and Wilson’s Disease Mutation Database: http://
www.wilsondisease.med.ualberta.ca/index.asp [21]). Most
mutations are extremely rare and limited to individual
patients. In studies of Caucasian populations, the
p.His1069Gln mutation represents 37% to 63% of muta-
tions [3,22]; however, the frequency and distribution of
ATP7B mutations in Chinese WND patients has not
been well studied. Only a few articles have reported
ATP7B mutations in the Chinese population [23-31],
and most of these studied only WND patients in the
southern part of China. The present study therefore
aimed to broaden the knowledge of ATP7B mutations
in Chinese patients to determine whether genotype/phe-
notype correlations could be established.
Methods
Patients and control
A total of 62 Wilson’s disease patients (58 probands)
from 58 unrelated families were included from five med-
ical centers in Shanghai, China (male, n = 37; female,
n = 25; age range, 2.6 ~ 61 years old). Most of patients
are children accounting for 80.6% (younger than
18 years old, n = 50). The clinical diagnosis of WND
was based on a combination of clinical manifestations,
laboratory tests and other features [1,2,32,33]. The main
criteria used to establish the diagnosis of WND
included: clinic manifestations, neurologic evaluation,
corneal Kayser-Fleischer rings (K-F rings), liver function
test, liver biopsy findings, liver copper concentration,
serum ceruloplasmin concentration (0.2 g/L,enzymatic
method), 24-h urinary copper concentration (upper
limit of normal [ULN], 40 μg/24 hours) (Inductively
Coupled Plasma Mass Spectrometry, America, Agilent)
and ATP7B genetic testing. Based on the scoring system
proposed at the 8th International Meeting on Wilson
Disease in Leipzig, Germany in 2001 [32,34], the diagno-
sis of WND was established with a cumulative score of
at least four.
Patients were classified according to clinical manifesta-
tions into the following groups: preclinical (presympto-
matic; identified by family screening), hepatic
manifestations (H1: acute hepatic WND; H2: chronic
hepatic WND), neurologic manifestations (N1:associated
with liver disease; N2: not associated with liver disease)
[32,35].
Genomic DNA from 100 healthy Chinese individuals
without WND was sequenced and analyzed to exclude
the possibility that newly identified mutations were rare
single nucleotide polymorphisms (SNPs).
Written informed consent was obtained from all
patients or patients’ legal guardians, and the study was
approved by The Ethical Committee of of Shanghai Jiao-
tong University in accordance with the Helsinki
Declaration.
Genomic DNA extraction and mutation analysis
Genomic DNA was extracted from peripheral blood
leukocytes with the Genomic DNA Purification Kit
(Qiagen, Germany). Entire exons and their associated
boundary regions were amplified by PCR with previously
reported primers [36]. PCR products were analyzed
using the Big-Dye Terminator Chemistry kit and the
ABI377 automated DNA sequencer (Applied Biosystems,
Foster City, CA, USA). The reference for cDNA
sequence of ATP7B was submitted to GenBank
(NM_000053.2). We used the standard nomenclature
recommendations of the Human Genome Variation
Society (HGVS) [37].
Statistical analysis
Continuous variables (age, and ceruloplasmin, serum
copper, and urinary copper concentrations) are
expressed as number (n), mean and standard deviation
(SD) or median and range. Continuous variables were
checked the distribution for normality by “KS normality
test” and “Shapiro-Wilk normality test”.C o n t i n u o u s
variables which were normally distributed were pre-
sented as mean and SD and were compared between
groups by ANOVA test and t tests. Continuous variables
which were not normally distributed in the analyzed
population were presented as median and range and
were compared between groups by Kruskal-Wallis
ANOVA test and Mann-Whitney U test. Discrete vari-
ables (neurologic, hepatic, or presymptomatic pheno-
types; presence or absence of K-F rings) were compared
by c
2 and Fisher’s exact test, and expressed as percen-
tages. Data were analyzed with SAS version 8.0. p < 0.05
was considered significant.
Systematic literature review
In order to expand our knowledge of ATP7B mutation
spectrum in Chinese population, we conducted a sys-
tematic review of the literature using the Wilson’sD i s -
ease Mutation Database [21] and PubMed (finalized on
July 1rst, 2010) with the combination of Wilson Disease
and mutation(s) in the search field. We reviewed
abstracts and retrieved articles that focused on the
Chinese population. Our systematic review conformed
to the guidelines laid out by PRISMA[38,39].
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Characterization of clinical phenotypes
We included 62 Chinese WND patients (58 probands)
in the present study. Of these, 56 (90.3%) presented
with liver disease, 4 (6.5%) were presymptomatic and
received a diagnosis by familial screening, 19 (32.7%)
presented with neurologic symptoms, and 25 (43.1%)
presented with K-F rings at the slit-lamp examination.
Presentations among the 56 patients with liver disease
included liver cirrhosis (n = 31), abnormal biochemical
liver function test results (n = 16), hepatic steatosis
(n = 6), hepatomegaly (n = 3), liver failure (n = 2), and
Coombs-negative hemolytic anemia (n = 1); other symp-
toms included fatigue, abdominal pain, edema, ascites,
and jaundice. Presentations among the 19 patients with
neurologic symptoms included deterioration in school-
work (n = 5), encephalatrophy (detected by magnetic
resonance imaging; n = 4), and trembling (n = 4); other
symptoms included drooling, weak limbs, dysarthria,
basal ganglia low-density lesions (detected by computed
tomography), lack of motor coordination, myotonia,
hearing loss, and inarticulacy. Median age at diagnosis
8.38 years (range 2.6 ~ 61), median age at symptom
onset 7.56 years (range 2.5 ~ 60.75), median diagnostic
delay was 4 months (range 2.6 ~ 61), median ceruloplas-
min level was 7.35g/L (range 1 ~ 23.9), median 24-h
urinary copper excretion was 222.5 μg per 24 h (rang 18
~ 1727) (87.1% patients > 1 × ULN, 75.8% patients >2 ×
ULN), and mean serum ALT level was 130 ± 94.3 IU/L
(66.7% patients > ULN, but 96% patients with abnormal
liver function were younger than 8 years old [n = 27]).
Compared with patients showing hepatic symptoms,
patients with neurologic manifestations were signifi-
cantly older at diagnosis (p < 0.0001; Figure 1A) and at
symptom onset (p = 0.0003; Figure 1B), and had a
longer diagnostic delay (p < 0.0001; Figure 1C), higher
rate of K-F rings (p < 0.0001; Figure 1D), lower serum
ALT levels (p = 0.0076; Figure 1E), and higher 24-h
urinary copper levels (Figure 1F; p = 0.0149) (Additional
file 1 : Supplementary TableS1).
Because corneal K-F ring is an important clinical sign
of WND, we compared patients positive for K-F rings
with those who did not show this sign. Compared with
K-F ring-negative patients, they were significantly older
at diagnosis (p < 0.0001; Figure 2A) and older at symp-
tom onset (p < 0.0001; Figure 2B), and had longer diag-
nostic delays tendency (p = 0.0556; Figure 2C), more
neurologic manifestations (p < 0.0001; Figure 2D), lower
serum ALT levels (p < 0.0001; Figure 2E), and higher
24-h urinary copper levels (p < 0.0001; Figure 2F) (Addi-
tional file 1 : Supplementary Table S2).
In addition, age at diagnosis was correlated with urin-
ary copper concentration (r = 0.58, p < 0.001; Figure 3).
Mutation analysis
By direct sequence analysis of the entire ATP7B gene
coding and promoter regions, we identified 40 different
mutations (missense mutations, n = 29; small deletion/
i n s e r t i o n s ,n=7 ;n o n s e n s em u t a t i o n s ,n=2 ;s p l i c e - s i t e
mutations, n = 2) that accounted for 94.4% of the WND
alleles in the 58 unrelated probands (Table 1). Of these
40 mutations, 14 were novel mutations that had not
been reported previously. Further, these mutations were
not found in the normal healthy Chinese participants
(n = 100), excluding potential polymorphisms. These
novel mutations include p.Glu611Lys, p.Ala874Pro,
p.Pro1014Leu, p.Cys1104Arg, p.Gly1149Glu, p.Gly1266Arg,
p.Asp1267Asn, p.Gly1335Arg, p.Glu332X, p.Cys271-
TrpfsX3, p.Arg483SerfsX20, p.Gly837GlyfsX17, p.Leu1053-
ProfsX16, p.Val1282CysfsX22 ( the sequence results are
shown in Additional file 1 : Supplementary figure S1 and
their location in the ATP7B g e n ee x o n si ss h o w ni nF i g u r e4 ) .
In the present study, mutations occurred most fre-
quently in exons 8 and 13 (Table 1). No mutations were
found in exons 1, 4, 6, 7, 9, or 21. The most frequent
WND mutation was p.Arg778Leu, which accounted for
31.9% of the 116 WND alleles studied, followed by p.
Pro992Leu (11.2%) and p.Ala874Val (5.17%). Of the 58
unrelated probands, we identified mutations in both
alleles (n = 53), in only one allele (n = 3), or in neither
allele (n = 2) (Both patients have corneal K-F ring posi-
tive, basal urine copper >80 μg/24h and ceruloplasmin <
20 mg/dl). In addition to the 40 mutations, 17 poly-
morphisms were also identified and are described in
detail in Additional file 1 : Supplementary Table S3.
Finally, linkage equilibrium was found between the
p.Arg778Leu mutation and the p.Leu770Leu polymorph-
ism as has already described [25].
Mutation spectrum of ATP7B in Chinese population
A PubMed search using the combined search terms of
Wilson Disease and mutation(s) retrieved a total of 899
publications. Of these, we analyzed only studies report-
ing well-defined mutations in Chinese patients [25-31].
To date, a total of 345 Chinese WND patients have
been studied (including the present study). Mutations
have been detected in all exons except exon 21. Most
WND mutations are located in exons 8, 13, 12, and 16,
which account for 74.0% of the reported WND alleles
(Figure 5). The most frequent WND mutations were
p.Arg778Leu and p.Pro992Leu, which account for
50.43% of all the reported WND alleles.
Genotype-phenotype correlation of the p.Arg778Leu
mutation
The 58 WND probands were analyzed for a potential geno-
type-phenotype correlation with respect to the p.Arg778Leu
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p.Arg778Leu mutation (n = 7) demonstrated more hepatic
manifestations (H1 or H2) and higher serum ALT levels
at diagnosis than patients heterozygous for this mutation
(n = 22; p = 0.028) or other mutations (n = 29; p = 0.0361)
(Figure 6A and 6C). In contrast, only one patient homozy-
gous for the p.Arg778Leu mutation showed neurologic
manifestations (N1). K-F rings were also less frequently
detected in p.Arg778Leu homozygous patients (14.3%) than
in p.Arg778Leu heterozygous patients (50%) or patients
Figure 1 Correlation of clinical manifestations with age at diagnosis (A), age at symptom onset (B), diagnostic delay (C), corneal
Kayser-Fleischer rings (D), alanine transaminase levels at diagnosis (E) and 24-h urinary copper excretion at diagnosis (F) in Chinese
patients with Wilson’s disease.
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significant differences were observed for age at symptom
onset, age at diagnosis, diagnostic delay, serum ceruloplas-
min levels, or basal urinary copper levels (Additional file 1 :
Supplementary Table S4).
Nonsense, frameshift, and splice-site mutations
Nonsense, frameshift, and splice-site mutations tend to
produce more severe functional impairment than mis-
sense mutations. We therefore, subdivided the muta-
tions into two groups: severe mutations (SMs), including
Figure 2 Correlation of cornea Kayser-Fleischer (K-F) ring with age at diagnosis (A), age at symptom onset (B), diagnostic delay (C),
corneal K-F Ring (D), ALT levels at diagnosis (E) and 24-h urinary copper levels at diagnosis (F) in Chinese patients with Wilson’s disease.
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Table 1 ATP7B gene mutations in 58 Chinese WD probands
Nucleotide
change
Nucleotide
Sequence
Amino acid
Change
exon Gene
region
No.of
alleles
Alleles frequency
(%)
Predicted Effect
Missense
*c.1831 G > A GAA > AAA p.Glu611Lys 5 Cu6 1 0.86 Cu6
c.2128 G > A GGT > AGT p.Gly710Ser 8 TM2 1 0.86 Affects copper transport
c.2293 G > A GAC > AAC p.Asp765Asn 8 TM4 1 0.86 Disrupt cation
channel&Tm4
c.2305 A > G ATG > GTG p.Met769Val 8 TM4 1 0.86 Affects copper transport
c.2333 G > T CGG > CTG p.Arg778Leu 8 TM4 37 31.9 Disrupt cation
channel&Tm4
*c.2620 G > C GCG > CCG p.Ala874Pro 11 TM5 1 0.86 Affects copper transport
c.2621 C > T GCG > GTG p.Ala874Val 11 TM5 6 5.17 Affects copper transport
c.2662 A > C ACC > CCC p.Thr888pro 11 TM5 1 0.86 Affects copper transport
c.2755 C > G CGG > GGG p.Arg919Gly 12 TM5 2 1.72 Affects copper transport
c.2785 A > G ATC > GTC p.Ile929Val 12 TM5 1 0.86 Affects copper transport
c.2804 C > T ACG > ATG p.Thr935Met 12 TM5 1 0.86 Disrupt cation
channel&Tm5
c.2924 C > A TCC > TAC p.Ser975Tyr 13 TM6 1 0.86 Disrupt cation
channel&Tm6
c.2939 G > A TGC > TAC p.Cys980Tyr 13 TM6 1 0.86 Disrupt cation
channel&Tm6
c.2975 C > T CCC > CTC p.Pro992Leu 13 TM6 13 11.2 Disrupt cation
channel&Tm6
*c.3041 C > T CCC > CTC p.Pro1014Leu 13 TM6 1 0.86 Affects copper transport
c.3284 A > C CAG > CCG p.Gln1095Pro 15 ATP loop 1 0.86 Disrupts ATP binding
*c.3310 T > C TGC > CGC p.Cys1104Arg 15 ATP loop 1 0.86 Disrupts ATP binding
c.3316 G > A GTC > ATC p.Val1106ILe 15 ATP loop 2 1.72 Disrupts ATP binding
c.3426 G > C CAG > CAC p.Gln1142His 16 ATP loop 1 0.86 Disrupts ATP binding
c.3443 T > C ATT > ACT p.Ile1148Thr 16 ATP loop 1 0.86 Disrupts ATP binding
*c.3446 G > A GGA > GAA p.Gly1149Glu 16 ATP loop 1 0.86 Disrupts ATP binding
c.3452 G > A CGT > CAT p.Arg1151His 16 ATP loop 2 1.72 Disrupts ATP binding
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c.3532 A > G ACA > GCA p.Thr1178Ala 16 ATP loop 1 0.86 Disrupts ATP binding
c.3646 G > A GTG > ATG p.Val1216Met 17 ATP bind 1 0.86 Disrupts ATP binding
*c.3796 G > C GGG > CGG p.Gly1266Arg 18 ATP loop 1 0.86 Disrupts ATP binding
*c.3799 G > A GAT > AAT p.Asp1267Asn 18 ATP hinge 1 0.86 Disrupt ATP hinge
c.3809 A > G AAT > AGT p.Asn1270Ser 18 ATP hinge 3 2.59 Disrupt ATP hinge
c.3889 G > A GTC > ATC p.Val1297Ile 18 ATP hinge 1 0.86 Disrupt ATP hinge
*c.4003 G > C GGG > CGG p.Gly1335Arg 19 TM7 2 1.72 Disrupt cation channel&
Tm7
Nonsense
*c.994 G > T GAA > TAA p.Glu332X 2 Cu4 3 2.59 Truncates protein
c.1470 C > A TGC > TGA p.Cys490X 3 Cu5 3 2.59 Truncates protein
Deletion
*c.813delC TTGCGTCT p.Cys271TrpfsX3 2 Cu3 1 0.86 Frame shift/Truncates
protein
*c.1448_1455del CCAGAGCAGTGGCA p.Arg483SerfsX20 3 Cu5 1 0.86 Frame shift/Truncates
protein
*c.2510delG GGGGAAA p.Gly837GlufsX35 10 TM4 1 0.86 Frame shift/Truncates
protein
Insertion
c.2304dupC CCCCATG p.Met769HisfsX26 8 TM4 4 3.45 Frame shift/Truncates
protein
c.2464dupA CCAATGG p.Met822AsnfsX32 10 TM4 3 2.59 Frame shift/Truncates
protein
*c.3157dupC CCCCTCA p.Leu1053ProfsX16 14 ATP loop 1 0.86 Frame shift/Truncates
protein
*c.3843dupT GGTTGTG p.Val1282CysfsX22 18 ATP hinge 1 0.86 Frame shift/Truncates
protein
Splice site
c.1708-5T > G ttg > tgg p.IVS4-5 T > G 5 Cu6 3 2.59 abnormal splicing
c.4124 + 5G > A gag > gaa p.IVS20 + 5 G > A 20 TM8 1 0.86 abnormal splicing
Novel mutations were denoted by asterisks. Cu,copper binding domain; TM,transmembrane domain.
Figure 4 Schematic representation of ATP7B mutations detected in the present study. The novel mutations identified in this study are
indicated in bold red letters.
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mutations; missense mutations (MMs). According to
this classification, we subdivided the patients into three
groups: SM/SM, patients possessing two severe muta-
tions (SMs); SM/MM, patients possessing one SM and
one missense mutation (MM); MM/MM, patients pos-
sessing two missense mutations.
All four patients in the SM/SM group presented with
hepatic manifestations (H1 or H2) and one patient pre-
sented with acute liver failure; statistics showed signifi-
cant differences among the three groups (p = 0.0383;
Figure 7A). The SM/SM group showed higher ALT
levels (p = 0.0061; Figure 7C), lower rate of K-F ring
detection (p = 0.0304; Figure 7B), and lower serum cer-
uloplasmin levels at diagnosis than other groups (p =
0.0065; Figure 7D,). No significant difference was
observed for age at symptom onset, diagnostic delay, age
at diagnosis, or urinary copper levels (Additional file 1 :
Supplementary Table S5).
Discussion
WND is a potentially fatal disease, but early diagnosis
and effective treatment can prevent disease progression
in symptomatic patients [9,40] and prevent symptom
development in presymptomatic patients. However, clin-
ical manifestations of WND are extraordinarily diverse,
and establishing the diagnosis is particularly difficult
with children [8,9]. In the present study, children
accounted for 80.6% of patients, 27 patients were chil-
dren younger than 8 years old at diagnosis. The children
often lacked typical symptoms: only two of the 27
patients presented with K-F rings, and 60% only had
abnormal liver function. Establishment of the diagnosis
of WND disease thus poses a major challenge to clini-
cians. Our data also show that the older the age at diag-
nosis and the longer the diagnosis delay the likelihood
of neurologic manifestations, indicating that early diag-
nosis and treatment may improve neurologic prognosis.
Therefore, rapid and inexpensi v ed i a g n o s t i cs t r a t e g i e s
are urgently needed in China.
Large-scale WND screening of the general population
[41] or of specific groups [42] has been considered to be
neither feasible nor cost-effective [40]. In 27 patients
(below the age of 8 years old at diagnosis), 96% had
abnormal liver function, 93% had low serum ceruloplas-
min (<0.2 g/L), 93% had high 24-h urinary copper
Figure 5 Distribution and frequency of ATP7B gene mutations from 345 patients with Wilson’s disease in the Chinese population
(including in this study).
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toms, and 93% patients lacked K-F rings. We therefore
recommend a three-step testing strategy for WND diag-
nosis for children younger than 8 years old: 1) liver
function test (to exclude other causes of hepatitis, such
as viral hepatitis etc.); 2) ceruloplasmin or urinary cop-
per test; 3) genetic testing. As physical examinations for
nursery school admission have become more common,
WND diagnosis in younger children has increased in
China (27 of 58 probands were younger than 8 years in
the present study). These improvements were gained in
part because of genetic testing and the three-step test
strategy for WND diagnosis.
Mutations have been detected throughout the ATP7B
gene, except exon 21, which makes the identification of
gene defects particularly challenging [8,9]. Therefore, a
rapid and cost-effective strategy is needed for genetic
testing. Studies of Chinese patients report that
Figure 6 Correlation of p.Arg778Leu mutation with clinical manifestations (A), cornea Kayser-Fleischer ring rate (B) and ALT levels at
diagnosis (C).
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for more than 74% of WND cases [25-31]. Therefore,
these four exons should be given high priority for
genetic testing in China.
More than 500 mutations have been identified in
patients with WND disease [21]. In the present study,
we detected 14 novel mutations in the Chinese Han
population. Six were nonsense or frameshift mutations;
the others were missense mutations that may produce
functional defects of transmembrane segments or the
ATP-binding domain. We have evaluated the possible
impact of missense mutations by using bioinformatic
tools SIFT[43], the results showed that all novel eight
missense mutations are predicted to affect protein func-
tion (data not shown). These results have expanded the
knowledge of ATP7B mutations and provided valuable
information to better understand the function of the
ATP7B protein.
Figure 7 Correlation of severe mutations (SMs) with clinical manifestations (A), corneal Kayser-Fleischer ring (B), ALT levels at
diagnosis (C) and serum ceruloplasmin (D). SM, nonsense mutation and frameshift mutations; missense mutations (MM); SM/SM, patients
possessing two severe mutations; SM/MM, patients possessing one severe and one missense mutation; MM/MM, patients possessing two
missense mutations.
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population is quite distinct from Western ethnic popula-
tions. Among Chinese patients, the most frequent WND
mutations were p.Arg778Leu and p.Pro992Leu, account-
ing for 50.43% of reported WND alleles. In contrast, the
p.His1069Gln, which the most frequent mutation in
Western populations [36,44,45], was not detected in any
Chinese patients. Clinical features of the p.Arg778Leu
mutation differed from those of p.His1069Gln [22,46].
In contrast to p.His1069Gln, patients with homozygous
p.Arg778Leu had more hepatic manifestations and fewer
neurologic manifestations than patients with heterozy-
gous p.Arg778Leu or other mutations [26,27]. Nonsense
and frameshift mutations were more strongly associated
with more hepatic manifestations, higher ALT levels,
fewer neurologic manifestations, and lower ceruloplas-
min levels than other mutations. These findings indicate
that the type of mutation can predict clinical manifesta-
tions. Interestingly, age at diagnosis, but not genotype,
was correlated with urinary copper concentration. This
information may account, in part, for the difficulty of
WND diagnosis in children [47,48].
This correlation between the p.Arg778Leu mutation
and clinical features may be due to functional defects in
the ATP7B protein, as demonstrated by the yeast com-
plementation assay [49]. Under iron-limited conditions,
p.Arg778Leu mutant constructs were unable to rescue
growth defects in Saccharomyces cerevisiae lacking the
CCC2 gene, but confocal images shows properly loca-
lized in COS-7 cell,[50], which suggests that the p.
Arg778Leu mutation disrupts the copper channel. In
contrast, frameshift/nonsense mutations can produce a
premature termination codon, potentially leading to
mRNA degradation by the RNA surveillance mechanism
[51], or a non-functional truncated protein, which
causes severe clinical phenotypes [35].
In summary, evaluating genotype-phenotype correla-
tions in WND will help understand the pathogenesis of
WND. The p.Arg778Leu, nonsense, and frameshift
mutations potentially lead to more severe disease at an
earlier age, usually with hepatic disease manifestations.
However, the genotype of ATP7B gene may not comple-
tely explain the phenotypic variability in WND patients.
Other factors that affect disease severity may include
levels of copper in diet or other genetic factors [52,53].
We reported the mutation spectrum in a total of
62 Chinese WND patients from 58 unrelated families.
Fourteen novel mutations were identified and the relation-
ship between genotypes and phenotypes were analyzed.
These results increase knowledge about the population
genetics of WND in China. The functional effects of these
new mutations require further investigation.
Conclusions
In conclusion, we identified 14 novel mutations and
found that the spectrum of mutations of ATP7B in China
i sq u i t ed i s t i n c tf r o mt h a to fW e s t e r nc o u n t r i e s .T h e
mutation type plays a role in predicting clinical manifes-
tations. Genetic testing is a valuable tool to detect WND
in young children, especially in patients younger than
8 years old. Four exons (8, 12, 13, and 16) and two muta-
tions (p.Arg778Leu, p.Pro992Leu) should be considered
high priority for cost-effective testing in China.
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detect Supplementary table S3 ATP7B polymorphisms found in Chinese
Wilson disease patients Supplementary table S4 Clinical data of 58 WD
probands and correlation with R778L Supplementary table S5 Clinical
data of 58 WD probands and correlation with severe mutation
Supplementary figure S1. 14 Novel mutations. Arrows indicate single
base substitutions; underlining indicates deleted bases; caret character
“^” indicates the inserted bases.
Acknowledgements
This project was supported by National Natural Science Foundation of China
(No. 30800612), Shanghai Educational Development Foundation (X.F, Kong
2007CG20) and National Special Key Grant (2008ZX10002 - 007). We also
thank Prof. Nelly Kieffer (CNRS-UMR7151, Sino-French Research Center for
Life Sciences and Genomics, Shanghai, China) for helpful discussions and
revising the English of the manuscript.
Author details
1Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong
University School of Medicine, Shanghai, China.
2Sino-French Research
Center for Life Sciences and Genomics, Ruijin Hospital, Shanghai Jiaotong
University School of Medicine, Shanghai, China.
3Institute of Infectious and
Respiratory Diseases, Ruijin Hospital, Shanghai Jiaotong University School of
Medicine, Shanghai, China.
4The Center for Pediatric Liver Diseases,
Children’s Hospital of Fudan University.
5Department of Pediatrics, Shanghai
Medical College, Fudan University, Shanghai, China.
6Liver Disease Research
Center, Nanjing Military Command, Shanghai, China.
7Department of
Infectious Diseases, No. 3 People’s Hospital, Shanghai Jiaotong University,
School of Medicine, Shanghai China.
8Department of Infectious Diseases, No.
6 People’s Hospital, Shanghai Jiaotong University, School of Medicine,
Shanghai, China.
Authors’ contributions
XHL performed the literature review, obtained the clinical data, Statistical
analysis and drafted the manuscript, with contributions from YLu, YL, YH,
JSW, XXZ. YLu, YL, QCF, JX, GQZ, FZ, QMG, DMY, YH, DHZ, XFK organized the
field survey for data collection and obtained the clinical data. XHL, YLu, YL,
ZML, XFK, JSW, XXZ were responsible for the design of the study. XHL, YLu,
YL were responsible for analysis and interpretation of data. XXZ, JSW were
responsible for critical revision of the manuscript for important intellectual
content. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 March 2010 Accepted: 11 January 2011
Published: 11 January 2011
Li et al. BMC Medical Genetics 2011, 12:6
http://www.biomedcentral.com/1471-2350/12/6
Page 11 of 13References
1. Roberts EA, Schilsky ML: Diagnosis and treatment of Wilson disease: an
update. Hepatology (Baltimore, Md 2008, 47(6):2089-2111.
2. Medici V, Rossaro L, Sturniolo GC: Wilson disease–a practical approach to
diagnosis, treatment and follow-up. Dig Liver Dis 2007, 39(7):601-609.
3. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML: Wilson’s disease. Lancet
2007, 369(9559):397-408.
4. Gitlin JD: Wilson disease. Gastroenterology 2003, 125(6):1868-1877.
5. Ferenci P: Pathophysiology and clinical features of Wilson disease.
Metabolic brain disease 2004, 19(3-4):229-239.
6. Tao TY, Gitlin JD: Hepatic copper metabolism: insights from genetic
disease. Hepatology (Baltimore, Md 2003, 37(6):1241-1247.
7. Ala A, Schilsky ML: Wilson disease: pathophysiology, diagnosis, treatment,
and screening. Clin Liver Dis 2004, 8(4):787-805, viii.
8. Riordan SM, Williams R: The Wilson’s disease gene and phenotypic
diversity. Journal of hepatology 2001, 34(1):165-171.
9. Schilsky ML: Wilson disease: current status and the future. Biochimie 2009,
91(10):1278-1281.
10. Iorio R, D’Ambrosi M, Mazzarella G, Varrella F, Vecchione R, Vegnente A:
Early occurrence of hypertransaminasemia in a 13-month-old child with
Wilson disease. J Pediatr Gastroenterol Nutr 2003, 36(5):637-638.
11. Beyersdorff A, Findeisen A: Morbus Wilson: Case report of a two-year-old
child as first manifestation. Scandinavian journal of gastroenterology 2006,
41(4):496-497.
12. Ala A, Borjigin J, Rochwarger A, Schilsky M: Wilson disease in
septuagenarian siblings: Raising the bar for diagnosis. Hepatology
(Baltimore, Md 2005, 41(3):668-670.
13. Petrukhin K, Fischer SG, Pirastu M, Tanzi RE, Chernov I, Devoto M,
Brzustowicz LM, Cayanis E, Vitale E, Russo JJ, et al: Mapping, cloning and
genetic characterization of the region containing the Wilson disease
gene. Nature genetics 1993, 5(4):338-343.
14. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW: The Wilson disease
gene is a putative copper transporting P-type ATPase similar to the
Menkes gene. Nature genetics 1993, 5(4):327-337.
15. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B,
Romano DM, Parano E, Pavone L, Brzustowicz LM, et al: The Wilson disease
gene is a copper transporting ATPase with homology to the Menkes
disease gene. Nature genetics 1993, 5(4):344-350.
16. White A, Tomfohrde J, Stewart E, Barnes R, Le Paslier D, Weissenbach J,
Cavalli-Sforza L, Farrer L, Bowcock A: A 4.5-megabase yeast artificial
chromosome contig from human chromosome 13q14.3 ordering 9
polymorphic microsatellites (22 sequence-tagged sites) tightly linked to
the Wilson disease locus. Proceedings of the National Academy of Sciences
of the United States of America 1993, 90(21):10105-10109.
17. Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY: Function and regulation of
human copper-transporting ATPases. Physiological reviews 2007,
87(3):1011-1046.
18. Lutsenko S, LeShane ES, Shinde U: Biochemical basis of regulation of
human copper-transporting ATPases. Archives of biochemistry and
biophysics 2007, 463(2):134-148.
19. Bartee MY, Lutsenko S: Hepatic copper-transporting ATPase ATP7B:
function and inactivation at the molecular and cellular level. Biometals
2007, 20(3-4):627-637.
20. de Bie P, Muller P, Wijmenga C, Klomp LW: Molecular pathogenesis of
Wilson and Menkes disease: correlation of mutations with molecular
defects and disease phenotypes. Journal of medical genetics 2007,
44(11):673-688.
21. Kenney SM, Cox DW: Sequence variation database for the Wilson disease
copper transporter, ATP7B. Human mutation 2007, 28(12):1171-1177.
22. Caca K, Ferenci P, Kuhn HJ, Polli C, Willgerodt H, Kunath B, Hermann W,
Mossner J, Berr F: High prevalence of the H1069Q mutation in East
German patients with Wilson disease: rapid detection of mutations by
limited sequencing and phenotype-genotype analysis. Journal of
hepatology 2001, 35(5):575-581.
23. Lee CC, Wu JY, Tsai FJ, Kodama H, Abe T, Yang CF, Tsai CH: Molecular
analysis of Wilson disease in Taiwan: identification of one novel
mutation and evidence of haplotype-mutation association. Journal of
human genetics 2000, 45(5):275-279.
24. Seto WK, Mak CM, But D, Hung I, Lam CW, Tam S, Yuen MF, Lai CL:
Mutational analysis for Wilson’s disease. Lancet 2009, 374(9690):662.
25. Mak CM, Lam CW, Tam S, Lai CL, Chan LY, Fan ST, Lau YL, Lai JY, Yuen P,
Hui J, et al: Mutational analysis of 65 Wilson disease patients in Hong
Kong Chinese: identification of 17 novel mutations and its genetic
heterogeneity. Journal of human genetics 2008, 53(1):55-63.
26. Gu YH, Kodama H, Du SL, Gu QJ, Sun HJ, Ushijima H: Mutation spectrum
and polymorphisms in ATP7B identified on direct sequencing of all
exons in Chinese Han and Hui ethnic patients with Wilson’s disease.
Clinical genetics 2003, 64(6):479-484.
27. Wan L, Tsai CH, Tsai Y, Hsu CM, Lee CC, Tsai FJ: Mutation analysis of
Taiwanese Wilson disease patients. Biochemical and biophysical research
communications 2006, 345(2):734-738.
28. Tsai CH, Tsai FJ, Wu JY, Chang JG, Lee CC, Lin SP, Yang CF, Jong YJ, Lo MC:
Mutation analysis of Wilson disease in Taiwan and description of six
new mutations. Human mutation 1998, 12(6):370-376.
29. Ye S, Gong L, Shui QX, Zhou LF: Wilson disease: identification of two
novel mutations and clinical correlation in Eastern Chinese patients.
World J Gastroenterol 2007, 13(38):5147-5150.
30. Wu ZY, Wang N, Lin MT, Fang L, Murong SX, Yu L: Mutation analysis and
the correlation between genotype and phenotype of Arg778Leu
mutation in chinese patients with Wilson disease. Archives of neurology
2001, 58(6):971-976.
31. Liu XQ, Zhang YF, Liu TT, Hsiao KJ, Zhang JM, Gu XF, Bao KR, Yu LH,
Wang MX: Correlation of ATP7B genotype with phenotype in Chinese
patients with Wilson disease. World J Gastroenterol 2004, 10(4):590-593.
32. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I,
Schilsky M, Cox D, Berr F: Diagnosis and phenotypic classification of
Wilson disease. Liver Int 2003, 23(3):139-142.
33. Goodman ZD: Grading and staging systems for inflammation and
fibrosis in chronic liver diseases. Journal of hepatology 2007, 47(4):598-607.
34. Ferenci P: Wilson’s Disease. Clin Gastroenterol Hepatol 2005, 3(8):726-733.
35. Gromadzka G, Schmidt HH, Genschel J, Bochow B, Rodo M, Tarnacka B,
Litwin T, Chabik G, Czlonkowska A: Frameshift and nonsense mutations in
the gene for ATPase7B are associated with severe impairment of copper
metabolism and with an early clinical manifestation of Wilson’s disease.
Clinical genetics 2005, 68(6):524-532.
36. Vrabelova S, Letocha O, Borsky M, Kozak L: Mutation analysis of the ATP7B
gene and genotype/phenotype correlation in 227 patients with Wilson
disease. Molecular genetics and metabolism 2005, 86(1-2):277-285.
37. den Dunnen JT, Antonarakis SE: Nomenclature for the description of
human sequence variations. Hum Genet 2001, 109(1):121-124.
38. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP,
Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. Annals of internal
medicine 2009, 151(4):W65-94.
39. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Annals of
internal medicine 2009, 151(4):264-269, W264.
40. Mak CM, Lam CW: Diagnosis of Wilson’s disease: a comprehensive
review. Critical reviews in clinical laboratory sciences 2008, 45(3):263-290.
41. Schilsky ML, Shneider B: Population screening for Wilson’s disease. J
Pediatr 2002, 140(5):499-501.
42. Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P:
Screening for Wilson’s disease in patients with liver diseases by serum
ceruloplasmin. Journal of hepatology 1997, 27(2):358-362.
43. Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect
protein function. Nucleic acids research 2003, 31(13):3812-3814.
44. Thomas GR, Roberts EA, Walshe JM, Cox DW: Haplotypes and mutations in
Wilson disease. American journal of human genetics 1995, 56(6):1315-1319.
45. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, Parano E,
Pavone L, Evgrafov O, Ivanova-Smolenskaya IA, et al: Identification and
analysis of mutations in the Wilson disease gene (ATP7B): population
frequencies, genotype-phenotype correlation, and functional analyses.
American journal of human genetics 1997, 61(2):317-328.
46. Stapelbroek JM, Bollen CW, van Amstel JK, van Erpecum KJ, van Hattum J,
van den Berg LH, Klomp LW, Houwen RH: The H1069Q mutation in ATP7B
is associated with late and neurologic presentation in Wilson disease:
results of a meta-analysis. Journal of hepatology 2004, 41(5):758-763.
47. Nicastro E, Loudianos G, Zancan L, D’Antiga L, Maggiore G, Marcellini M,
Barbera C, Marazzi MG, Francavilla R, Pastore M, et al: Genotype-phenotype
Li et al. BMC Medical Genetics 2011, 12:6
http://www.biomedcentral.com/1471-2350/12/6
Page 12 of 13correlation in Italian children with Wilson’s disease. Journal of hepatology
2009, 50(3):555-561.
48. Schmidt HH: Role of genotyping in Wilson’s disease. Journal of hepatology
2009, 50(3):449-452.
49. Iida M, Terada K, Sambongi Y, Wakabayashi T, Miura N, Koyama K, Futai M,
Sugiyama T: Analysis of functional domains of Wilson disease protein
(ATP7B) in Saccharomyces cerevisiae. FEBS letters 1998, 428(3):281-285.
50. Park S, Park JY, Kim GH, Choi JH, Kim KM, Kim JB, Yoo HW: Identification of
novel ATP7B gene mutations and their functional roles in Korean
patients with Wilson disease. Human mutation 2007, 28(11):1108-1113.
51. Chang YF, Imam JS, Wilkinson MF: The nonsense-mediated decay RNA
surveillance pathway. Annu Rev Biochem 2007, 76:51-74.
52. Coronado VA, Bonneville JA, Nazer H, Roberts EA, Cox DW: COMMD1
(MURR1) as a candidate in patients with copper storage disease of
undefined etiology. Clinical genetics 2005, 68(6):548-551.
53. de Bie P, van de Sluis B, Klomp L, Wijmenga C: The many faces of the
copper metabolism protein MURR1/COMMD1. The Journal of heredity
2005, 96(7):803-811.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/6/prepub
doi:10.1186/1471-2350-12-6
Cite this article as: Li et al.: Clinical and molecular characterization of
Wilson’s disease in China: identification of 14 novel mutations. BMC Medical
Genetics 2011 12:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. BMC Medical Genetics 2011, 12:6
http://www.biomedcentral.com/1471-2350/12/6
Page 13 of 13